Biotech Lock-Up Expiration Hell Portfolio Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Lock-Up Expiration Hell Portfolio

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: hmpa who wrote (48)	5/26/2001 7:39:49 PM
From: Biomaven	Read Replies (2) of 1005

If a doctor writes a scrip for the combo, I do not believe the pharmacist could substitute the two generics. Further, a benefits manager would be delighted to substitute this drug (at a price well above the two generics) for an expensive triptan. The POZN trials showed comparable efficacy with a low-dose triptan. I believe there is a large unmet need for migraine treatment one notch below the triptans but above OTC Excedrin or NSAIDS. Few doctors are aware of the efficacy of the metoclopramide/naprosyn combo. I very much doubt many would go to the trouble of writing two scripts and explaining to the patient that they need to take them together, aside from the compliance issues that might result. I do have some concern about the use of metoclopramide, with TD (tardive dyskinesia) being a worrisome (but rare) side-effect. Domperidome (Motilium) would likely have been a better choice (it doesn't cross the blood-brain barrier), but it is unfortunately not available in the US, although it is OTC in the UK and Europe. The bottom line here though is that these guys have gotten excellent clinical trial results in a very large but still under-served area. Peter

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next